
Agios Pharmaceuticals stock jumps 67% on strong Q2 revenue and FDA Priority Review for sickle cell drug
Agios Pharmaceuticals saw its stock surge after H.C. Wainwright raised the price target to $55, implying a 67% upside. The company reported Q2 2026 revenues of $44.75 million, nearly doubling estimates, driven by strong sales of its drug mitapivat (P...



